Menu
Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Its Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company's sales from continuing operations reached $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.
135 Duryea Rd
Melville, New York 11747-3834
Phone: 16318435500
www.henryschein.com
In collaboration with the Association of Dental Support Organizations (ADSO), Henry Schein, Inc. (Nasdaq: HSIC) today announced that it will present a pre-conference program on Tuesday, March 28 from 2:30 – 5:30 pm at the 2023 ADSO Annual Summit. Open to all registered attendees for ADSO’s Annual Summit, Henry Schein’s program is titled “Innovative Solutions for Unprecedented Times: How
Media Briefing to Discuss "Integrated Digital Dentistry and the Future of Data, Devices, and Software" in Oral Health, featuring Henry Schein Chairman and Chief Executive Officer Stanley M. Bergma…
Henry Schein has proven in last earnings report they are capable of increasing revenues despite certain headwinds. Check out what makes HSIC stock a buy.
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2023 World’s Most Ethical Companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230310005322/en/
https://www.investing.com/news/pro/henry-schein-pt-lowered-to-80-at-jpmorgan-432SI-3025031
How to use Henry Schein HSIC as a Forecasting Tool
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, is hosting an Investor Meeting today in New York City at 9 a.m. EST, where executive leadership will provide an overview of the Company’s BOLD+1 Strategic Plan for sustainable growth and details about the Company’s long-term financial goals. “Since
The S&P 500 snapped a four-session losing streak, recording gains on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga''s insider transactions platform. Henry Schein The Trade: Henry Schein, Inc. (NASDAQ: HSIC ) Director Bradley T Sheares sold a total of 11,243 shares at an average price of $82.07. The insider received around $922.71 thousand from selling those shares. What’s Happening: Henry … Full story available on Benzinga.com
Henry Schein, Inc. (NASDAQ:NASDAQ:HSIC) Q4 2022 Earnings Conference Call February 16, 2023 10:00 AM ETCompany ParticipantsGraham Stanley - VP, IR & Strategic Finance Project…
The following slide deck was published by Henry Schein, Inc.
Henry Schein Inc (NASDAQ: HSIC ) posts Q4 FY22 sales of $3.37 billion , beating the consensus of $3.34 billion. The 1.2% increase included a 1.8% decrease in local currencies excluding acquisitions, 1.1% growth from acquisitions, and a 3.0% decrease related to foreign currency exchange, while the extra week of sales contributed 4.9% to sales growth. Sales of PPE products and COVID-19 test kits in the … Full story available on Benzinga.com
Henry Schein (HSIC) issued 2023 earnings per share guidance that is well above the consensus estimate.
MELVILLE (dpa-AFX) - Henry Schein Inc. (HSIC) released earnings for fourth quarter that decreased from last year but beat the Street estimates.The company''s earnings came in at $47 million, or $0….
MELVILLE, N.Y. (AP) — MELVILLE, N.Y. (AP) — Henry Schein Inc. (HSIC) on Thursday reported fourth-quarter net income of $47…
https://www.investing.com/news/stock-market-news/henry-schein-earnings-matched-revenue-topped-estimates-3005464
Henry Schein press release (HSIC): Q4 Non-GAAP EPS of $1.21 misses by $0.01.Revenue of $3.4B (+2.1% Y/Y) beats by $30M.Introduces guidance for 2023 non-GAAP diluted EPS of $5.25…
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein reports fourth-quarter and full-year 2022 financial results and introduces 2023 financial guidance.
Henry Schein (HSIC) is scheduled to announce Q4 earnings results on Thursday, February 16th, before market open.The consensus EPS Estimate is $1.22 (+14.0% Y/Y) and the consensus…
Henry Schein (NASDAQ: HSIC ) is set to give its latest quarterly earnings report on Thursday, 2023-02-16. Here''s what investors need to know before the announcement. Analysts estimate that Henry Schein will report an earnings per share (EPS) of $1.21. Henry Schein bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Stocks that traded heavily or had substantial price changes Monday: Fidelity, Norfolk Southern fall; Teradata, Henry Schein rise
Henry Schein (HSIC) Board of Directors has authorized the repurchase of up to $400M of shares.This program is in addition to the $400M repurchase program announced in August 2022, which…
Henry Schein Inc. said Monday that it has authorized a new $400 million share repurchase program. Based on Friday’s closing price for the medical product…
Henry Schein, Inc. (Nasdaq: HSIC), the world''s largest provider of health care products and services to office-based dental and medical practitioners, announced today that its Board of Directors has authorized the repurchase of up to $400 million of shares of the Company''s common stock. This program is in addition to the $400 million repurchase program announced in August 2022, which is anticipated
Major players in the clear aligners market are Align Technology, Henry Schein, Institut Straumann, The 3M Company, Danaher Corporation (Ormco Corporation), Dentsply Sirona, Scheu Dental, Great Lakes Dental Technologies, TP Orthodontics, and K-Line Europe. Major players in the clear aligners market are Align Technology, Henry Schein, Institut Straumann, The 3M Company, Danaher Corporation (Ormco Corporation), Dentsply Sirona, Scheu Dental, Great Lakes Dental Technologies, TP Orthodontics, and K-Line Europe.
Henry Schein''s ''resiliency'' premium is still well in situ leading into the new year. Read more to see why we reiterate our Buy rating on HSIC stock.
The latest update on Global E-Prescription Market study provides comprehensive valuable insights on the market development activities demonstrated by industry players, growth opportunities, and market sizing for E-Prescription, complete with analysis by key segments, leading and emerging players and geographies